Natural products as pharmacological modulators of mitochondrial dysfunctions for the treatments of Alzheimer’s disease: A comprehensive review

Xin Jin,Jia-Ling Guo,Lin Wang,Xin Zhong,Wei-Fan Yao,Hua Gao,Ming-Yan Liu
DOI: https://doi.org/10.1016/j.ejmech.2021.113401
IF: 7.088
2021-06-01
European Journal of Medicinal Chemistry
Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">s</h2><p>Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder characterized by neuronal loss and cognitive impairment that harshly affect the elderly individuals. Currently, the available anti-AD pharmacological approaches are purely symptomatic to alleviate AD symptoms, and the curative effects of novel anti-AD drugs focused on Aβ target are disappointing. Hence, there is a tremendous need to adjust AD therapeutic targets and discover novel anti-AD agents. In AD, mitochondrial dysfunction gradually triggers neuronal death from different aspects and worsens the occurrence and progress of AD. Consequently, it has been proposed that the intervention of impaired mitochondria represents an attractive breakthrough point for AD treatments. Due to chemical diversity, poly-pharmacological activities, few adverse effects and multiple targeting, natural products (NPs) have been identified as a valuable treasure for drug discovery and development. Multiple lines of studies have scientifically proven that NPs display ameliorative benefits in AD treatment in relation to mitochondrial dysfunction. This review surveys the complicated implications for mitochondrial dysregulation and AD, and then summarizes the potentials of NPs and their underlying molecular mechanisms against AD via reducing or improving mitochondrial dysfunction. It is expected that this work may open the window to speed up the development of innovative anti-AD drugs originated from NPs and improve upcoming AD therapeutics.</p>
chemistry, medicinal
What problem does this paper attempt to address?